Related Experiment Video

Updated: Oct 13, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Cyclosporin A in the treatment of CLL associated PRCA and bone marrow hypoplasia

S Tura1, C Finelli, G Bandini

  • 1Institute of Haematology L. e A. Serágnoli, University of Bologna, Italy.

Nouvelle Revue Francaise D'Hematologie
|January 1, 1988
PubMed

Insights

Cyclosporin A (CS-A) effectively treated bone marrow failure in three patients with chronic lymphocytic leukemia (CLL). This immunosuppressive therapy induced rapid remission with minimal side effects, suggesting its potential use in similar cases.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Bone marrow failure is a serious complication in chronic lymphocytic leukemia (CLL).
  • Conventional immunosuppressive therapies often fail to induce remission in these cases.
  • Cyclosporin A (CS-A) is an immunosuppressant with potential applications in hematologic disorders.

Observation:

  • Three patients with CLL-associated bone marrow failure were treated with CS-A.
  • One patient had relapsed during steroid therapy.
  • Two patients were resistant to standard immunosuppressive treatments.

Findings:

  • CS-A induced prompt remission of bone marrow failure within 1-4 weeks in all three patients.
  • The only observed side effect was mild, reversible renal toxicity.
  • CS-A demonstrated efficacy in steroid-resistant and conventionally resistant cases.

Implications:

  • CS-A may be a viable therapeutic option for managing bone marrow failure in CLL patients.
  • Further investigation into CS-A's role in CLL complications is warranted.
  • This approach could offer an alternative for patients refractory to standard treatments.

More Related Videos

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Colony-Forming Unit Assay Adapted For Patient-Derived Bone Marrow and Peripheral Blood Mononuclear Cells08:50

Colony-Forming Unit Assay Adapted For Patient-Derived Bone Marrow and Peripheral Blood Mononuclear Cells

Published on: June 26, 2026

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...